{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T09:02:44Z","timestamp":1771664564945,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1805523N"],"award-info":[{"award-number":["1805523N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"DOI":"10.1007\/s12016-026-09137-7","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T06:35:49Z","timestamp":1771655749000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cytoreduction is a Valid Option for Treatment and Prevention of Anaphylaxis in Systemic Mastocytosis: Case Report and Literature Review"],"prefix":"10.1007","volume":"69","author":[{"given":"Toon","family":"Ieven","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inge","family":"Govaerts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glynis","family":"Frans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martijn","family":"Vandebotermet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastiaan","family":"Tuyls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Wilmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rik","family":"Schrijvers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Vandenberghe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Breynaert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,21]]},"reference":[{"issue":"1","key":"9137_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-025-00611-8","volume":"11","author":"C Akin","year":"2025","unstructured":"Akin C, Arock M, Carter MC, George TI, Valent P, Mastocytosis (2025) Nat Rev Dis Primers 11(1):30","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"9137_CR2","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/j.1398-9995.2007.01569.x","volume":"63","author":"K Brockow","year":"2008","unstructured":"Brockow K, Jofer C, Behrendt H, Ring J (2008) Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 63(2):226\u2013232","journal-title":"Allergy"},{"issue":"4","key":"9137_CR3","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.jaip.2019.02.002","volume":"7","author":"M Castells","year":"2019","unstructured":"Castells M, Butterfield J (2019) Mast cell activation syndrome and mastocytosis: initial treatment options and long-term management. J Allergy Clin Immunol Pract 7(4):1097\u20131106","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"9137_CR4","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/cea.13592","volume":"50","author":"F Jendoubi","year":"2020","unstructured":"Jendoubi F, Gaudenzio N, Gallini A, Negretto M, Paul C, Bulai Livideanu C (2020) Omalizumab in the treatment of adult patients with mastocytosis: a systematic review. Clin Exp Allergy 50(6):654\u2013661","journal-title":"Clin Exp Allergy"},{"issue":"6","key":"9137_CR5","doi-asserted-by":"publisher","first-page":"EVIDoa2200339","DOI":"10.1056\/EVIDoa2200339","volume":"2","author":"J Gotlib","year":"2023","unstructured":"Gotlib J, Castells M, Elberink HO, Siebenhaar F, Hartmann K, Broesby-Olsen S et al (2023) Avapritinib versus placebo in indolent systemic mastocytosis. NEJM Evid 2(6):EVIDoa2200339","journal-title":"NEJM Evid"},{"key":"9137_CR6","volume":"51","author":"L Bergmann","year":"1985","unstructured":"Bergmann L, Mittrou P (1985) Recombinant gamma-interferon in the treatment of a patient with malignant mastocytosis. Blut 51:218","journal-title":"Blut"},{"issue":"9","key":"9137_CR7","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1056\/NEJM199202273260907","volume":"326","author":"HC Kluin-Nelemans","year":"1992","unstructured":"Kluin-Nelemans HC, Jansen JH, Breukelman H, Wolthers BG, Kluin PM, Kroon HM et al (1992) Response to interferon alfa-2b in a patient with systemic mastocytosis. N Engl J Med 326(9):619\u2013623","journal-title":"N Engl J Med"},{"issue":"5\u20136","key":"9137_CR8","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3109\/10428199609054789","volume":"22","author":"AS Worobec","year":"1996","unstructured":"Worobec AS, Kirshenbaum AS, Schwartz LB, Metcalfe DD (1996) Treatment of three patients with systemic mastocytosis with interferon alpha-2b. Leuk Lymphoma 22(5\u20136):501\u2013508","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"9137_CR9","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1046\/j.1365-2133.1998.02131.x","volume":"138","author":"JH Butterfield","year":"1998","unstructured":"Butterfield JH (1998) Response of severe systemic mastocytosis to interferon alpha. Br J Dermatol 138(3):489\u2013495","journal-title":"Br J Dermatol"},{"issue":"4","key":"9137_CR10","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1159\/000204898","volume":"85","author":"S Pardini","year":"1991","unstructured":"Pardini S, Bosincu L, Bonfigli S, Dore F, Longinotti M (1991) Anaphylactic-like syndrome in systemic mastocytosis treated with alpha-2-interferon. Acta Haematol 85(4):220","journal-title":"Acta Haematol"},{"issue":"12","key":"9137_CR11","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1007\/s002770000206","volume":"79","author":"GH Schernthaner","year":"2000","unstructured":"Schernthaner GH, Spanbl\u00f6chl E, Sperr WR, Sillaber C, Semper H, Jurecka W et al (2000) Effects of interferon-alpha2b treatment on ex vivo differentiation of mast cells from circulating progenitor cells in a patient with systemic mastocytosis. Ann Hematol 79(12):660\u20136","journal-title":"Ann Hematol"},{"issue":"11","key":"9137_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3000530","volume":"17","author":"T Kobayashi","year":"2019","unstructured":"Kobayashi T, Shimabukuro-Demoto S, Tsutsui H, Toyama-Sorimachi N (2019) Type i interferon limits mast cell-mediated anaphylaxis by controlling secretory granule homeostasis. PLoS Biol 17(11):e3000530","journal-title":"PLoS Biol"},{"issue":"12","key":"9137_CR13","doi-asserted-by":"publisher","first-page":"4125","DOI":"10.1182\/blood.V93.12.4125","volume":"93","author":"A Saven","year":"1999","unstructured":"Saven A, Burian C (1999) Cladribine activity in adult langerhans-cell histiocytosis. Blood 93(12):4125\u20134130","journal-title":"Blood"},{"issue":"8","key":"9137_CR14","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s00277-023-05180-y","volume":"102","author":"J L\u00fcbke","year":"2023","unstructured":"L\u00fcbke J, Naumann N, Metzgeroth G, Kreil S, Brand T, Horny HP et al (2023) Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysis. Ann Hematol 102(8):2077\u201385","journal-title":"Ann Hematol"},{"issue":"13","key":"9137_CR15","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1182\/blood-2003-05-1699","volume":"102","author":"HC Kluin-Nelemans","year":"2003","unstructured":"Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, Van \u2019t Wout JW, Verhoef G, Gerrits WBJ et al (2003) Cladribine therapy for systemic mastocytosis. Blood 102(13):4270\u20134276","journal-title":"Blood"},{"issue":"2","key":"9137_CR16","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0145-2126(03)00185-1","volume":"28","author":"A Pardanani","year":"2004","unstructured":"Pardanani A, Hoffbrand AV, Butterfield JH, Tefferi A (2004) Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine. Leuk Res 28(2):127\u2013131","journal-title":"Leuk Res"},{"issue":"4","key":"9137_CR17","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1159\/000329218","volume":"157","author":"F Wimazal","year":"2012","unstructured":"Wimazal F, Geissler P, Shnawa P, Sperr WR, Valent P (2012) Severe life-threatening or disabling anaphylaxis in patients with systemic mastocytosis: a single-center experience. Int Arch Allergy Immunol 157(4):399\u2013405","journal-title":"Int Arch Allergy Immunol"},{"issue":"8","key":"9137_CR18","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1182\/blood-2014-12-614743","volume":"126","author":"S Barete","year":"2015","unstructured":"Barete S, Lortholary O, Damaj G, Hirsch I, Chandesris MO, Elie C et al (2015) Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis. Blood 126(8):1009\u20131016 quiz 1050","journal-title":"Blood"},{"issue":"9","key":"9137_CR19","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.exphem.2010.05.006","volume":"38","author":"A B\u00f6hm","year":"2010","unstructured":"B\u00f6hm A, Sonneck K, Gleixner KV, Schuch K, Pickl WF, Blatt K et al (2010) In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V. Exp Hematol 38(9):744\u201355","journal-title":"Exp Hematol"},{"key":"9137_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00443","volume":"11","author":"M Piris-Villaespesa","year":"2020","unstructured":"Piris-Villaespesa M, Alvarez-Twose I (2020) Systemic mastocytosis: following the tyrosine kinase inhibition roadmap. Front Pharmacol 11:443","journal-title":"Front Pharmacol"},{"issue":"5","key":"9137_CR21","doi-asserted-by":"publisher","first-page":"328","DOI":"10.18176\/jiaci.1077","volume":"35","author":"LV Carpio-Escalona","year":"2025","unstructured":"Carpio-Escalona LV, Prieto-Garc\u00eda A, Morales-Cabeza C, Guilarte M, Matito A, Torrado I et al (2025) Tyrosine kinase inhibitors for the treatment of mast cell diseases: review and update. J Investig Allergol Clin Immunol 35(5):328\u2013340","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"12","key":"9137_CR22","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.1158\/1078-0432.CCR-08-0366","volume":"14","author":"S Verstovsek","year":"2008","unstructured":"Verstovsek S, Tefferi A, Cortes J, O\u2019Brien S, Garcia-Manero G, Pardanani A et al (2008) Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 14(12):3906\u20133915","journal-title":"Clin Cancer Res"},{"issue":"11","key":"9137_CR23","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.leukres.2008.12.020","volume":"33","author":"A Vega-Ruiz","year":"2009","unstructured":"Vega-Ruiz A, Cortes JE, Sever M, Manshouri T, Quint\u00e1s-Cardama A, Luthra R et al (2009) Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res 33(11):1481\u20134","journal-title":"Leuk Res"},{"issue":"6","key":"9137_CR24","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1182\/blood-2007-08-104372","volume":"111","author":"M Kneidinger","year":"2008","unstructured":"Kneidinger M, Schmidt U, Rix U, Gleixner KV, Vales A, Baumgartner C et al (2008) The effects of dasatinib on IgE receptor-dependent activation and Histamine release in human basophils. Blood 111(6):3097\u20133107","journal-title":"Blood"},{"issue":"5","key":"9137_CR25","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.18632\/oncotarget.3074","volume":"6","author":"S Cerny-Reiterer","year":"2015","unstructured":"Cerny-Reiterer S, Rabenhorst A, Stefanzl G, Herndlhofer S, Hoermann G, M\u00fcllauer L et al (2015) Long-term treatment with Imatinib results in profound mast cell deficiency in Ph\u2009+\u2009chronic myeloid leukemia. Oncotarget 6(5):3071\u20133084","journal-title":"Oncotarget"},{"issue":"4","key":"9137_CR26","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1080\/14712598.2021.1837109","volume":"21","author":"J Gotlib","year":"2021","unstructured":"Gotlib J, Kluin-Nelemans HC, Akin C, Hartmann K, Valent P, Reiter A (2021) Practical management of adverse events in patients with advanced systemic mastocytosis receiving midostaurin. Expert Opin Biol Ther 21(4):487\u2013498","journal-title":"Expert Opin Biol Ther"},{"issue":"26","key":"9137_CR27","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","volume":"374","author":"J Gotlib","year":"2016","unstructured":"Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O et al (2016) Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med 374(26):2530\u20132541","journal-title":"N Engl J Med"},{"issue":"2","key":"9137_CR28","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/leu.2017.234","volume":"32","author":"DJ DeAngelo","year":"2018","unstructured":"DeAngelo DJ, George TI, Linder A, Langford C, Perkins C, Ma J et al (2018) Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. Leukemia 32(2):470\u2013478","journal-title":"Leukemia"},{"issue":"2","key":"9137_CR29","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.jaci.2020.03.044","volume":"146","author":"K Hartmann","year":"2020","unstructured":"Hartmann K, Gotlib J, Akin C, Hermine O, Awan FT, Hexner E et al (2020) Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis. J Allergy Clin Immunol 146(2):356-366.e4","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"9137_CR30","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jaci.2018.06.003","volume":"142","author":"B van Anrooij","year":"2018","unstructured":"van Anrooij B, Oude Elberink JNG, Span LFR, de Monchy JGR, Rosati S, Mulder AB et al (2018) Midostaurin in patients with indolent systemic mastocytosis: an open-label phase 2 trial. J Allergy Clin Immunol 142(3):1006-1008.e7","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"9137_CR31","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1038\/s41591-021-01538-9","volume":"27","author":"DJ DeAngelo","year":"2021","unstructured":"DeAngelo DJ, Radia DH, George TI, Robinson WA, Quiery AT, Drummond MW et al (2021) Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nat Med 27(12):2183\u20132191","journal-title":"Nat Med"},{"issue":"6","key":"9137_CR32","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1016\/j.jaip.2021.02.040","volume":"9","author":"E Kudlaty","year":"2021","unstructured":"Kudlaty E, Perez M, Stein BL, Bochner BS, Kuang FL (2021) Systemic mastocytosis with an associated hematologic neoplasm complicated by recurrent anaphylaxis: prompt resolution of anaphylaxis with the addition of avapritinib. J Allergy Clin Immunol Pract 9(6):2534\u20132536","journal-title":"J Allergy Clin Immunol Pract"},{"key":"9137_CR33","volume":"2025","author":"S Worth","year":"2025","unstructured":"Worth S, George TI, Shaheen DJ, Roche M, Vachhani P (2025) Chronic anaphylaxis with indolent systemic mastocytosis: A case report. Case Rep Hematol 2025:9562195","journal-title":"Case Rep Hematol"},{"issue":"2","key":"9137_CR34","first-page":"355","volume":"13","author":"L Degenfeld-Schonburg","year":"2023","unstructured":"Degenfeld-Schonburg L, Gamperl S, Stefanzl G, Schruef AK, Sadovnik I, Bauer K et al (2023) Antineoplastic efficacy profiles of avapritinib and nintedanib in KIT D816V\u2009+\u2009systemic mastocytosis: a preclinical study. Am J Cancer Res 13(2):355\u2013378","journal-title":"Am J Cancer Res"},{"issue":"11","key":"9137_CR35","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1111\/j.1365-2222.2009.03353.x","volume":"39","author":"MT Krauth","year":"2009","unstructured":"Krauth MT, Mirkina I, Herrmann H, Baumgartner C, Kneidinger M, Valent P (2009) Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells. Clin Exp Allergy 39(11):1711\u20131720","journal-title":"Clin Exp Allergy"},{"issue":"10","key":"9137_CR36","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1056\/NEJMoa2408792","volume":"392","author":"M Metz","year":"2025","unstructured":"Metz M, Gim\u00e9nez-Arnau A, Hide M, Lebwohl M, Mosnaim G, Saini S et al (2025) Remibrutinib in chronic spontaneous urticaria. N Engl J Med 392(10):984\u2013994","journal-title":"N Engl J Med"},{"key":"9137_CR37","doi-asserted-by":"crossref","unstructured":"Suresh RV, Dunnam C, Vaidya D, Wood RA, Bochner BS, MacGlashan DW et al (2023) A phase II study of bruton\u2019s tyrosine kinase Inhibition for the prevention of anaphylaxis. J Clin Invest. ;133(16)","DOI":"10.1172\/JCI172335"},{"issue":"2","key":"9137_CR38","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11882-023-01123-9","volume":"24","author":"V Sabato","year":"2024","unstructured":"Sabato V, Beyens M, Toscano A, Van Gasse A, Ebo DG (2024) Mast cell-targeting therapies in mast cell activation syndromes. Curr Allergy Asthma Rep 24(2):63\u201371","journal-title":"Curr Allergy Asthma Rep"},{"issue":"Supplement 1","key":"9137_CR39","doi-asserted-by":"publisher","first-page":"4595","DOI":"10.1182\/blood-2021-152770","volume":"138","author":"A Guarnieri","year":"2021","unstructured":"Guarnieri A, Chicarelli M, Cable L, Bouhana K, Sullivan F, Ball H et al (2021) Preclinical data with KIT D816V inhibitor Bezuclastinib (CGT9486) demonstrates high selectivity and minimal brain penetrance. Blood 138(Supplement 1):4595\u20134595","journal-title":"Blood"},{"issue":"1","key":"9137_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clml.2024.06.005","volume":"25","author":"HT Chifotides","year":"2025","unstructured":"Chifotides HT, Bose P (2025) SOHO state of the art update and next questions: current and emerging therapies for systemic mastocytosis. Clin Lymphoma Myeloma Leuk 25(1):1\u201312","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"9137_CR41","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1016\/j.jaci.2025.07.019","volume":"156","author":"SE Lee","year":"2025","unstructured":"Lee SE, Bouzid H, Kwan C, Sharma A, Romo AR, Huang R et al (2025) Anti-KIT antibody, briquilimab, induces mast cell apoptosis and depletion in nonhuman primates. J Allergy Clin Immunol 156(5):1328\u201340","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"9137_CR42","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1111\/all.15585","volume":"78","author":"D Terhorst-Molawi","year":"2023","unstructured":"Terhorst-Molawi D, Hawro T, Grekowitz E, Kiefer L, Merchant K, Alvarado D et al (2023) Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria. Allergy 78(5):1269\u20131279","journal-title":"Allergy"},{"issue":"8","key":"9137_CR43","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1111\/all.16598","volume":"80","author":"M Maurer","year":"2025","unstructured":"Maurer M, Metz M, Anderson J, Talreja N, Young D, Crowley E et al (2025) Anti-KIT barzolvolimab for chronic spontaneous urticaria. Allergy 80(8):2178\u201386","journal-title":"Allergy"},{"key":"9137_CR44","unstructured":"Kwon HS, Lee SE, Sharma A, Youn M, Chang CA, Wells A et al (2025) Human KIT Antibody Briquilimab Diminishes Anaphylactic Responses in Mice Expressing Chimeric Human-Mouse KIT. Allergy"},{"issue":"1","key":"9137_CR45","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/all.15850","volume":"79","author":"M Metz","year":"2024","unstructured":"Metz M, Kolkhir P, Altrichter S, Siebenhaar F, Levi-Schaffer F, Youngblood BA et al (2024) Mast cell silencing: a novel therapeutic approach for urticaria and other mast cell-mediated diseases. Allergy 79(1):37\u201351","journal-title":"Allergy"},{"issue":"5","key":"9137_CR46","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1093\/bjd\/ljad191","volume":"189","author":"F Siebenhaar","year":"2023","unstructured":"Siebenhaar F, Altrichter S, Bonnekoh H, Hawro T, Hawro M, Michaelis EG et al (2023) Safety and efficacy of lirentelimab in patients with refractory indolent systemic mastocytosis: a first-in-human clinical trial. Br J Dermatol 189(5):511\u2013519","journal-title":"Br J Dermatol"},{"key":"9137_CR47","doi-asserted-by":"crossref","unstructured":"Chhiba KD, Saini SS (2025) Emerging IgE and non-IgE targeted therapies for chronic urticaria. Ann Allergy Asthma Immunol","DOI":"10.1016\/j.anai.2025.11.008"},{"issue":"4","key":"9137_CR48","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.jaci.2024.07.002","volume":"154","author":"J Wollam","year":"2024","unstructured":"Wollam J, Solomon M, Villescaz C, Lanier M, Evans S, Bacon C et al (2024) Inhibition of mast cell degranulation by novel small molecule MRGPRX2 antagonists. J Allergy Clin Immunol 154(4):1033\u201343","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"9137_CR49","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1016\/j.jaip.2023.02.021","volume":"11","author":"P Valent","year":"2023","unstructured":"Valent P, Hartmann K, Bonadonna P, Sperr WR, Niedoszytko M, Hermine O et al (2023) European Competence Network on Mastocytosis (ECNM): 20-year jubilee, updates, and future perspectives. J Allergy Clin Immunol Pract 11(6):1706\u201317","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-026-09137-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-026-09137-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-026-09137-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T08:02:30Z","timestamp":1771660950000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-026-09137-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,21]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9137"],"URL":"https:\/\/doi.org\/10.1007\/s12016-026-09137-7","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,21]]},"assertion":[{"value":"16 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee Research UZ\/KU Leuven (study number S59230). The patient provided written informed consent for publication of clinical data in the case report section.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}],"article-number":"9"}}